Canrenone

DB12221InvestigationalSmall molecule

Canrenone is an antimineralocorticoid and active metabolite of spironolactone used in the treatment of primary hyperaldosteronism and edematous states caused by secondary hyperaldosteronism (e.g. heart failure). A diuretic medication used in the treatment of heart failure, high blood pressure, and other conditions involving fluid retention.

Chemical structure of Canrenone
Mechanism
Curator reviewed
Formula / weight
C22H28O3 · 340.4559 g/mol (avg)
Code names
SC-9376

Resolves to

Compound
UNII78O20X9J0UCAS976-71-6ChEMBLCHEMBL1463345ChEBI135445PubChem13789
Clinical / RWD
RxNorm1982ATCC03DA03
Structure
InChIKeyUJVLDDZCTMKXJK-WNHSNXHDSA-NSMILES[H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@]12C
Targets
P08235NR3C2

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
910Drug interactionsStructured to mechanism, not free text
Sign in
6Clinical trialsPhase, status and sponsor resolved per trial
Sign in
3Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
6ContraindicationsEach with its own population and attribute set
Sign in
7Marketed productsAcross 1 country and 1 labeller
Sign in
1ATC codeIncluding every combination product, plus 11 drug categories
Sign in
6+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Canrenone, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In